Phillip Frost - Opko Health Chairman of the Board, CEO
| OPK Stock | USD 1.23 0.02 1.60% |
Chairman
Dr. Phillip Frost serves as Chairman of the Board and Chief Executive Officer at Opko health, Inc. Dr. Frost was the Chief Executive Officer of the Company and Chairman of the Board since March 2007. Dr. Frost serves as a director for Castle Brands, a developer and marketer of premium brand spirits, and Cocrystal Pharma, Inc., a publicly traded biotechnology company developing new treatments for viral diseases. He serves as a member of the Board of Trustees of the University of Miami, the Skolkovo Foundation Scientific Advisory Council in Russia, the Shanghai Institute for Advanced Immunochemical Studies in China, and The Florida Council of 100 and as a Trustee of each of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He serves as Chairman of Temple EmanuEl, Governor of Tel Aviv University and is a member of the Executive Committee of The Phillip and Patricia Frost Museum of Science. Dr. Frost served as a director of Ladenburg Thalmann Financial Services Inc., an investment banking, asset management, and securities brokerage firm providing services through its principal operating subsidiary, Ladenburg Thalmann Co. Inc., from 2004 to 2018 and had served as its Chairman from July 2006 until September 2018, a director of Teva Pharmaceutical Industries, Limited, or Teva from January 2006 until February 2015 and had served as Chairman of the Board of Teva from March 2010 until December 2014. Dr. Frost previously served as Vice Chairman of Cogint, Inc., now known as Fluent, Inc., and as a director for Sevion Therapeutics, Inc. prior to its merger with Eloxx Pharmaceuticals, Inc., and TransEnterix, Inc., . Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. Dr. Frost was Chairman of the Board of Directors of Key Pharmaceuticals, Inc. since 2007.
| Age | 88 |
| Tenure | 17 years |
| Address | 4400 Biscayne Boulevard, Miami, FL, United States, 33137 |
| Phone | 305 575 4100 |
| Web | https://www.opko.com |
Phillip Frost Latest Insider Activity
Tracking and analyzing the buying and selling activities of Phillip Frost against Opko Health stock is an integral part of due diligence when investing in Opko Health. Phillip Frost insider activity provides valuable insight into whether Opko Health is net buyers or sellers over its current business cycle. Note, Opko Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Opko Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Phillip Frost over a month ago Acquisition by Phillip Frost of 500000 shares of Opko Health at 0.9275 subject to Rule 16b-3 | ||
Phillip Frost over a month ago Acquisition by Phillip Frost of 600000 shares of Opko Health at 0.9323 subject to Rule 16b-3 | ||
Phillip Frost over two months ago Acquisition by Phillip Frost of 1000000 shares of Opko Health at 0.9917 subject to Rule 16b-3 |
Opko Health Management Efficiency
The company has Return on Asset of (0.0473) % which means that on every $100 spent on assets, it lost $0.0473. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.128) %, meaning that it generated no profit with money invested by stockholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.41. The value of Return On Capital Employed is expected to slide to -0.09. At this time, Opko Health's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to 0.00 this year, although the value of Total Current Liabilities will most likely fall to about 103.9 M.Similar Executives
| Found 11 records | CHAIRMAN Age | ||
| Matthew Rabinowitz | Natera Inc | 51 | |
| Ming Hsieh | Fulgent Genetics | 68 | |
| Giovanni Lettieri | 23Andme Holding Co | 58 | |
| Michael Goldberg | Caredx Inc | 60 | |
| Jonathan Ayers | IDEXX Laboratories | 61 | |
| Boon Koh | Agilent Technologies | 70 | |
| William Rastetter | Illumina | 66 | |
| Jay Flatley | Illumina | 65 | |
| James Cullen | Agilent Technologies | 72 | |
| Daniel Bradbury | Castle Biosciences | 57 | |
| Mats Olsson | 23Andme Holding Co | 63 | |
Management Performance
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0473 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arie Gutman, Pres API | ||
| Dr MBA, Vice Officer | ||
| FACP FASN, Senior Renal | ||
| David Okrongly, President Diagnostics | ||
| Antonio Cruz, President Therapeutics | ||
| Dmitry Kolosov, Independent Director | ||
| Richard Lerner, Independent Director | ||
| Thomas Nusbickel, Chief Commercial Officer of the Company's Renal Division | ||
| Elias MD, President Chairman | ||
| Richard Pfenniger, Independent Director | ||
| Philip Frost, Chairman of the Board, CEO | ||
| Thomas Beier, Director | ||
| Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
| Jon Cohen, Executive Chairman of BioReference Laboratories | ||
| Robert Fishel, Independent Director | ||
| Robert Baron, Independent Director | ||
| Anne Fields, IR Contact Officer | ||
| Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
| Alice Yu, Independent Director | ||
| Steven Rubin, Executive Vice President - Administration, Director | ||
| JD Esq, Chief Laboratories | ||
| Charles Bishop, Chief Renal | ||
| Hans Berner, President Iberoamerica | ||
| James DeMarco, VP Sales | ||
| John Paganelli, Independent Director | ||
| Phillip Frost, Chairman of the Board, CEO | ||
| Miriam Miller, IR Contact Officer | ||
| MBA MBA, Vice Officer | ||
| Jon MD, Advisor | ||
| Jane Hsiao, Vice Chairman of the Board, Chief Technical Officer | ||
| Geoff Monk, President of BioReference | ||
| Richard Krasno, Independent Director |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0473 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.38) % | ||||
| Current Valuation | 1.09 B | ||||
| Shares Outstanding | 696.99 M | ||||
| Shares Owned By Insiders | 52.40 % | ||||
| Shares Owned By Institutions | 25.05 % | ||||
| Number Of Shares Shorted | 93.61 M | ||||
| Price To Earning | 7.46 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Opko Stock please use our How to buy in Opko Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Opko Stock analysis
When running Opko Health's price analysis, check to measure Opko Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opko Health is operating at the current time. Most of Opko Health's value examination focuses on studying past and present price action to predict the probability of Opko Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opko Health's price. Additionally, you may evaluate how the addition of Opko Health to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Opko Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opko Health. If investors know Opko will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opko Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.191 | Earnings Share (0.25) | Revenue Per Share 1.149 | Quarterly Revenue Growth (0.02) | Return On Assets (0.05) |
The market value of Opko Health is measured differently than its book value, which is the value of Opko that is recorded on the company's balance sheet. Investors also form their own opinion of Opko Health's value that differs from its market value or its book value, called intrinsic value, which is Opko Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opko Health's market value can be influenced by many factors that don't directly affect Opko Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opko Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Opko Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opko Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.